Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study - The Lancet Oncology
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer - Lung Cancer
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
First-line Durvalumab Improves Survival
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Stage III NSCLC - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
PACIFIC 5-Yr Update - Capsule Summary Slidesets - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
PACIFIC survival explained: Cancer spread red | EurekAlert!
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
Durvalumab - Wikipedia
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Decision making process diagram to evaluate candidate patients for... | Download Scientific Diagram
PACIFIC phase III trial scheme. | Download Scientific Diagram
